1. Deciphering the age-dependent changes of pulmonary fibroblasts in mice by single-cell transcriptomics
    Rundong Wu et al, 2023, Frontiers in Cell and Developmental Biology CrossRef
  2. SARS-CoV-2 diagnosis: a single-centre experience
    Ion Maruntelu et al, 2021, Journal of Medicine and Life CrossRef
  3. Healing after COVID-19: are survivors at risk for pulmonary fibrosis?
    Lindsay T. McDonald, 2021, American Journal of Physiology-Lung Cellular and Molecular Physiology CrossRef
  4. β-Carboline Alkaloids From the Deep-Sea Fungus Trichoderma sp. MCCC 3A01244 as a New Type of Anti-pulmonary Fibrosis Agent That Inhibits TGF-β/Smad Signaling Pathway
    Meng-Jiao Hao et al, 2022, Frontiers in Microbiology CrossRef
  5. Mortality and Its Predictors in COVID-19 Patients With Pre-existing Interstitial Lung Disease
    Naveen Dutt et al, 2022, Cureus CrossRef
  6. Pulmonary complications due to COVID-19 – a literature review
    Anna Maria Romaszko-Wojtowicz et al, 2021, Polish Annals of Medicine CrossRef
  7. Overview of the pathogenesis of COVID‑19 (Review)
    Chao Li et al, 2021, Experimental and Therapeutic Medicine CrossRef
  8. Radiologically suspected COVID‑19‑associated organizing pneumonia responding well to corticosteroids: A report of two cases and a review of the literature
    Christos Siafarikas et al, 2022, Experimental and Therapeutic Medicine CrossRef
  9. The Impact of the COVID-19 Pandemic on Dementia Risk: Potential Pathways to Cognitive Decline
    Jeffrey D. Pyne et al, 2021, Neurodegenerative Diseases CrossRef
  10. An interpretable deep learning workflow for discovering subvisual abnormalities in CT scans of COVID-19 inpatients and survivors
    Longxi Zhou et al, 2022, Nature Machine Intelligence CrossRef
  11. Impact of the COVID-19 Pandemic on Trends in Cardiothoracic Imaging
    Kathleen M. Capaccione et al, 2022, Radiology Research and Practice CrossRef
  12. Lung Transplantation in Patients With COVID-19-The Early National Experience
    Isabella S. Florissi et al, 2023, Seminars in Thoracic and Cardiovascular Surgery CrossRef
  13. The Role of Cytokines and Chemokines in Severe Acute Respiratory Syndrome Coronavirus 2 Infections
    Ren-Jun Hsu et al, 2022, Frontiers in Immunology CrossRef
  14. A case of successful treatment of diffuse post-coronavirus pulmonary fibrosis with pirfenidone
    Svitlana Bychkova et al, 2023, Polish Annals of Medicine CrossRef
  15. Irreversible Lung Transformation Resulting from Damage In COVID-19 — Discourses and Examples of CT Images
    A. S. Vinokurov et al, 2022, The Russian Archives of Internal Medicine CrossRef
  16. Prospects for the use of bovhyaluronidase azoxymer in the post-COVID period after a severe COVID-19: A clinical case
    Tatiana A. Sergeeva et al, 2023, Psychopharmacology & biological narcology CrossRef
  17. S2k-Leitlinie – Empfehlungen zur stationären Therapie von Patienten mit COVID-19
    S. Kluge et al, 2021, Pneumologie CrossRef
  18. The pathogenesis, epidemiology and biomarkers of susceptibility of pulmonary fibrosis in COVID-19 survivors
    Andrea Vianello et al, 2022, Clinical Chemistry and Laboratory Medicine (CCLM) CrossRef
  19. The effect of Pirfenidone on pulmonary function parameters in post recovery COVID-19 patients with pulmonary fibrosis compared to placebo in a Government Medical College, West Bengal
    Tanmoy Banerjee et al, 2022, Biomedicine CrossRef
  20. Molecular mechanisms of COVID-19-induced pulmonary fibrosis and epithelial-mesenchymal transition
    Peng Pi et al, 2023, Frontiers in Pharmacology CrossRef
  21. Respiratorische Viren, COVID und Lungenfibrose – alles wie beim ARDS oder doch anders?
    Fotios Drakopanagiotakis et al, 2021, Kompass Pneumologie CrossRef
  22. Dual inhibition of CB1 receptors and iNOS, as a potential novel approach to the pharmacological management of acute and long COVID‐19
    Resat Cinar et al, 2022, British Journal of Pharmacology CrossRef
  23. Dynamic role of LMW-hyaluronan fragments and Toll-like receptors 2,4 in progression of bleomycin induced lung parenchymal injury to fibrosis
    Apoorva Pandey et al, 2021, The Egyptian Journal of Bronchology CrossRef
  24. Pathogenetic bases of the use of antifibrotic therapy with Bovhyaluronidazum azoximerum in patients with new coronavirus infection COVID-19
    O. A. Chernyavskaya et al, 2021, Meditsinskiy sovet = Medical Council CrossRef
  25. Dihydroartemisinin attenuates pulmonary inflammation and fibrosis in rats by suppressing JAK2/STAT3 signaling
    Xiaolan You et al, 2022, Aging CrossRef
  26. Cardiopulmonary disease as sequelae of long-term COVID-19: Current perspectives and challenges
    Rudolf K. F. Oliveira et al, 2022, Frontiers in Medicine CrossRef
  27. Long‑term effects of COVID‑19 in sickle cell disease: A case report
    Ricardo Alberca et al, 2021, World Academy of Sciences Journal CrossRef
  28. Histopathological and molecular links of COVID-19 with novel clinical manifestations for the management of coronavirus-like complications
    Ankita Sood et al, 2022, Inflammopharmacology CrossRef
  29. The Atrium in Atrial Fibrillation – A Clinical Review on How to Manage Atrial Fibrotic Substrates
    Pedro Silva Cunha et al, 2022, Frontiers in Cardiovascular Medicine CrossRef
  30. Commonalities Between ARDS, Pulmonary Fibrosis and COVID-19: The Potential of Autotaxin as a Therapeutic Target
    Konstantinos Ntatsoulis et al, 2021, Frontiers in Immunology CrossRef
  31. Materdicine and Medmaterial
    Hui HUANG et al, 2022, Journal of Inorganic Materials CrossRef
  32. TRPM7 restrains plasmin activity and promotes transforming growth factor-β1 signaling in primary human lung fibroblasts
    Sarah Zeitlmayr et al, 2022, Archives of Toxicology CrossRef
  33. Temporal Patterns of COVID-19-Associated Pulmonary Pathology: An Autopsy Study
    George S Stoyanov et al, 2021, Cureus CrossRef
  34. PHYSIOTHERAPY REHABILITATION IN LONG COVID: A CASE SERIES
    Khushali Jain et al, 2020, INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH CrossRef
  35. Tracking the time course of pathological patterns of lung injury in severe COVID-19
    Thais Mauad et al, 2021, Respiratory Research CrossRef
  36. Pulmonary Fibrosis Progression Prediction Using Image Processing and Machine Learning
    Amr Essam Aboeleneen et al, 2021, Emerging Technologies in Biomedical Engineering and Sustainable TeleMedicine CrossRef
  37. mTOR-Inhibition and COVID-19 in Kidney Transplant Recipients: Focus on Pulmonary Fibrosis
    Simona Granata et al, 2021, Frontiers in Pharmacology CrossRef
  38. Gamma Delta T Cells and Their Involvement in COVID-19 Virus Infections
    Georg von Massow et al, 2021, Frontiers in Immunology CrossRef
  39. Sequelae, persistent symptomatology and outcomes after COVID-19 hospitalization: the ANCOHVID multicentre 6-month follow-up study
    Álvaro Romero-Duarte et al, 2021, BMC Medicine CrossRef
  40. Mesenchymal Stromal/Stem Cells and Their Extracellular Vesicles Application in Acute and Chronic Inflammatory Liver Diseases: Emphasizing on the Anti-Fibrotic and Immunomodulatory Mechanisms
    Ali Hazrati et al, 2022, Frontiers in Immunology CrossRef
  41. Prospects of Hyaluronidase Therapy in Novel COVID-19 Infection with Damage to Lungs
    Aleksandra V. Solov’yeva et al, 2022, I.P. Pavlov Russian Medical Biological Herald CrossRef
  42. Pathogenesis of pulmonary fibrosis
    M.G. Rybakova et al, 2024, Russian Journal of Archive of Pathology CrossRef
  43. Post-COVID-19 Pulmonary Fibrosis
    Asma Mohammadi et al, 2022, Cureus CrossRef
  44. Pulmonary Manifestations of COVID-19
    Sivakumar Nagaraju et al, 2024, Textbook of SARS-CoV-2 and COVID-19 CrossRef
  45. PTPα promotes fibroproliferative responses after acute lung injury
    Yael Aschner et al, 2022, American Journal of Physiology-Lung Cellular and Molecular Physiology CrossRef